5471-77-2

Usage

Synthesis Reference(s)

Tetrahedron Letters, 15, p. 2721, 1974 DOI: 10.1016/S0040-4039(01)91723-X

InChI:InChI=1/C7H12O4/c1-4-11-6(10)7(2,3)5(8)9/h4H2,1-3H3,(H,8,9)

Upstream product

• 1619-62-1 2,2-dimethylmalonic acid diethyl ester 
• 541-41-3 chloroformic acid ethyl ester 
• 79-31-2 isobutyric Acid 
• 124-38-9 carbon dioxide 
• 97-62-1 Ethyl isobutyrate 
• 14002-73-4 3-hydroxy-2,2-dimethyl-propionic acid ethyl ester 
• 801301-34-8 2-dimethylstibanyl-2-methylpropionic acid ethyl ester 
• 3495-36-1 cesium formate 
• 97-63-2 methyl methacrylate 

Downstream Products

• 64244-87-7 2-chlorocarbonyl-2-methylpropanoic acid ethyl ester 
• 33367-54-3 diethyl 2,2,3,3-tetramethylsuccinate 
• 858195-82-1 ethyl 2-nitrooxyisobutyrate 
• 97-63-2 methyl methacrylate 
• 1619-62-1 2,2-dimethylmalonic acid diethyl ester 
• 97-62-1 Ethyl isobutyrate 
• 229636-60-6 3-[6-(3-benzylureido)indolin-1-yl]-2,2-dimethyl-3-oxopropanoic acid 
• 403599-98-4 ethyl 3-[6-(3-benzylureido)indolin-1-yl]-2,2-dimethyl-3-oxopropanoate 
• 1026913-43-8 (R,S)-ethyl 3-{3-[6-(3-benzylureido)indolin-1-yl]-2,2-dimethyl-3-oxopropanoylamino}-3-(pyridin-3-yl)propanoate 
• 342797-12-0 (3R)-3,7,7-trimethyl-3-phenylpyrrolo[2,1-c][1,4]oxazine-1,4,6,8-tetraone 
• 342797-11-9 ethyl (2'R)-2,2-dimethyl-3-(2'-methyl-3',6'-dioxo-2'-phenylmorpholin-4'-yl)-3-oxopropionate 
• 342797-13-1 (3R,8aR)-8a-hydroxymethyl-3,7,7-trimethyl-3-phenylpyrrolo[2,1-c][1,4]oxazine-1,4,6,8-tetraone 
• 342797-16-4 (3R,8S,8aR)-8-Hydroxy-8a-hydroxymethyl-3,7,7-trimethyl-3-phenyl-dihydro-pyrrolo[2,1-c][1,4]oxazine-1,4,6-trione 
• 138683-46-2 N-(2,6-Diisopropyl-phenyl)-2,2-dimethyl-malonamic acid ethyl ester 

Relevant academic research and scientific papers

Oxadiazole and thiadiazole compounds and preparation methods and applications thereof

The invention discloses oxadiazole and thiadiazole compoundsand preparation methods and applications thereof.The compounds is shown as a formula I or a formula II.The oxadiazole or thiadiazole compound or a pharmaceutically acceptable salt, racemate, opti

Controlling Plasma Stability of Hydroxamic Acids: A MedChem Toolbox

Hydroxamic acids are outstanding zinc chelating groups that can be used to design potent and selective metalloenzyme inhibitors in various therapeutic areas. Some hydroxamic acids display a high plasma clearance resulting in poor in vivo activity, though they may be very potent compounds in vitro. We designed a 57-member library of hydroxamic acids to explore the structure-plasma stability relationships in these series and to identify which enzyme(s) and which pharmacophores are critical for plasma stability. Arylesterases and carboxylesterases were identified as the main metabolic enzymes for hydroxamic acids. Finally, we suggest structural features to be introduced or removed to improve stability. This work thus provides the first medicinal chemistry toolbox (experimental procedures and structural guidance) to assess and control the plasma stability of hydroxamic acids and realize their full potential as in vivo pharmacological probes and therapeutic agents. This study is particularly relevant to preclinical development as it allows obtaining compounds equally stable in human and rodent models.

Discovery of potent c-MET inhibitors with new scaffold having different quinazoline, pyridine and tetrahydro-pyridothienopyrimidine headgroups

Cellular mesenchymal-epithelial transition factor (c-MET) is closely linked to human malignancies, which makes it an important target for treatment of cancer. In this study, a series of 3-methoxy-N-phenylbenzamide derivatives, N-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl) benzamide derivatives and N1-(3-fluoro-4-methoxyphenyl)-N3-(4-fluorophenyl) malonamide derivatives were designed and synthesized, some of them were identified as c-MET inhibitors. Among these compounds with new scaffolds having different quinazoline, pyridine and tetrahydro-pyridothienopyrimidine head groups, compound 11c, 11i, 13b, 13h exhibited both potent inhibitory activities against c-MET and high anticancer activity against tested cancer cell lines in vitro. In addition, kinase selectivity assay further demonstrated that both 13b and 13h are potent and selective c-MET inhibitors. Molecular docking supported that they bound well to c-MET and VEGFR2, which demonstrates that they are potential c-MET RTK inhibitors for cancer therapy.

METHOD OF PRODUCING CARBOXYLATE

PROBLEM TO BE SOLVED: To provide a method of producing useful chemicals of carboxylates through hydrocarboxylation reaction of olefins by effectively utilizing carbon dioxide without using any expensive reducing agent. SOLUTION: A method of producing a carboxylate represented by the general formula (3) includes reacting an olefin with a formate represented by the general formula (2). (An+ is an n-valent cation; n is an integer from 1 to 4; and R1 to R4 are each independently H or a C1-24 organic group, where two or more of the R1 to R4 may be connected with each other.) SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT

PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF

This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.

Generation of carbanions through stibine-metal and bismuthine-metal exchange reactions and its applications to precision synthesis of ω-end-functionalized polymers

Generation of carbanions from organostibines and organobismuthines through heteroatom-metal exchange reactions was examined from synthetic and mechanistic viewpoints. The exchange reaction proceeded spontaneously upon treatment with various organometallic reagents, such as alkyl lithiums, tetraalkyl zincates, and alkyl magnesium halides to afford the corresponding carbanions quantitatively. Due to the high reactivity of these heteroatom compounds, the exchange reactions took place exclusively even in the presence of various polar functional groups, which potentially react with organometallic species. The advantage of this method was exemplified by the end-group transformation of living polymers that bear these heteroatom species at the ω-polymer end, prepared by using organostibine and bismuthine-mediated living radical polymerizations. Various polymers that bear polar functional groups and acidic hydrogen-for example, poly(methyl methacrylate), poly(butyl acrylate), poly(N-isopropyl acrylamide), and poly(2-hydroxyethyl methacrylate)-could be used in the exchange reactions, and subsequent trapping with electrophiles afforded the corresponding polymers with controlled molecular weights, molecular weight distributions, and end-group functionalities. Competition experiments showed that organostibines and organobismuthines were among the most reactive heteroatom compounds towards organometallic reagents and that their high reactivity was responsible for the high chemoselectivity in the exchange reaction. All's well that ends well: The generation of carbanions from organostibine and -bismuthine compounds was achieved thorough a heteroatom-metal exchange reaction (see scheme). The highly chemoselective exchange reaction could be applied to precision synthesis of varieties of ω-end- functionalized polymers that possess a polar functional group.

Compounds Which Selectively Modulate The CB2 Receptor

Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Hydroxamates: Relationships between structure and plasma stability

Hydroxamates are valuable tools for chemical biology as well as interesting leads for medicinal chemistry. Although many hydroxamates display nanomolar activities against metalloproteases, only three hydroxamates have reached the market, among which is the HDAC inhibitor vorinostat. Failures in development are generally attributed to lack of selectivity, toxicity, or poor stability. To help medicinal chemists with respect to plasma stability, we have performed the first and preliminary study on structure-plasma stability for hydroxamates. We define some structural rules to predict or improve the plasma stability in the preclinical stage.

NOVEL 6-5 BICYCIC HETEROCYCLIC DERIVATIVE AND MEDICAL USE THEREOF

An object of the present invention is to provide a medicament as a thyroid hormone receptor ligand which is sufficient in drug efficacy and safety, and has the excellent action as a drug. The present invention provides a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof: [wherein [Chemical Formula 2] is a single bond or a double bond; A is -CH2- or -CO-; X, Y, and Z are each independently a nitrogen atom or a carbon atom; R1 is a hydrogen atom or an aralkyl group; R2 is an alkyl group or an aralkyl group, etc.; R3 is a hydrogen atom or an alkyl group, etc.; R4 is a hydrogen atom or an alkyl group; R5 is a hydrogen atom, an alkyl group or a halo lower alkyl group, etc.; R6 is a hydrogen atom or an alkyl group; R7 is a hydrogen atom, etc.; R8 is a hydrogen atom, or an alkyl group, etc.; and E is -NHCO-G-COR12, etc. (wherein G is a single bond or an alkylene group, and R12 is a hydroxy group or an alkoxy group)].

BICYCLO HETEROCYCLIC COMPOUND HAVING ANTIFUNGAL ACTION

It is intended to provide a 1,6-β-glucan synthase inhibitor which strongly inhibits proliferation and has a high safety. It is intended to provide a compound which can specifically or selectively expressing an antifungal action on a broad spectrum based on the action mechanism of inhibiting the synthesis of 1,6-β-glucan. Further, it is intended to provide a drug, in particular, an antifungal agent containing the above compound, its salt or a hydrate thereof. More specifically speaking, a compound represented by the following general formula (I), its salt or a hydrate thereof; and a drug or an antifungal agent containing the above compound, its salt or a hydrate thereof.